Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN ...
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results